<DOC>
	<DOCNO>NCT01679470</DOCNO>
	<brief_summary>This open-label , single-center , single-dose efficacy pilot study AuroLase Therapy treatment subject primary and/or metastatic tumor lung airway obstruction . In study patient give systemic IV infusion particle subsequent escalate dose laser radiation deliver optical fiber via bronchoscopy .</brief_summary>
	<brief_title>Efficacy Study AuroLase Therapy Subjects With Primary and/or Metastatic Lung Tumors</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Subjects must document histological cytological evidence tumor ( ) lung . Subjects must one primary metastatic tumor lung least 10 mm long axis evaluate spiral CT scan evaluation perform within last 30 day . Target lesion accessible examination ( examination fiberoptic bronchoscopy permit ) biopsy . Each index lesion large enough provide least 6 mg tumor tissue biopsy assessment neutron activation analysis . Tumors must measurable accord RECIST criterion . Subjects must ECOG Performance Score 0 , 1 2 . Subjects must ≥ 18 year age . Subjects legal representative must able read , understand sign inform consent . Adequate renal function evidence serum creatinine ≤ 2.0 mg/dL . Adequate hepatic function evidence : Serum total bilirubin ≤ 2.0 mg/dL ; Alkaline phosphatase ≤ 2X ULN reference lab ; SGOT/SGPT ≤ 2X ULN reference lab . Women childbearing potential must agree use effective form contraception study 90 day follow treatment ( effective form contraception oral contraceptive double barrier method ) . Women NOT childbearing potential undergone bilateral oophorectomy undergone menopause , define absence menstrual cycle 12 consecutive month . Negative pregnancy test woman childbearing potential . Subjects know hypersensitivity component PEGylated AuroShell suspension ( polyethylene glycol , gold ) . Patients pregnant and/or lactating . Patients undergone splenectomy . Subjects receive concurrent investigational therapy receive investigational therapy within 30 day prior AuroShell infusion ( investigational therapy define treatment currently regulatory authority approve indication ) . Subjects evidence active bacterial infection fever ≥ 38.5 ºC ( 101.3 ºF ) within 3 day first schedule day dose . Subject course radiotherapy treatment area within 30 day prior AuroShell infusion . Subject course chemotherapy antineoplastic therapy 30 day prior AuroShell infusion . Life expectancy le 3 month . Any medical condition , include mental illness substance abuse , deem Investigator likely interfere subject 's ability sign inform consent , cooperate participate study , interfere interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>lung</keyword>
	<keyword>laser</keyword>
	<keyword>ablation</keyword>
	<keyword>airway obstruction</keyword>
</DOC>